hemas investor presentation q1 20202010 2013 2016 0 500 1,000 1,500 2,000 2,500 monthly household...

Investor PresentationHemas Holdings PLC

Q1 FY 2019–2020

August 22, 2019

Hemas Holdings PLC: Our portfolio

Copyright © 2019 Hemas Holdings PLC | www.hemas.com 2

Cons

umer

Healthcare

Leisure Mobili

ty

Home & Personal care SL

Home & Personal care International

School & Office Supplies

Pharma Manufacture

Digital Healthcare

Pharma Distribution

Hospitals

Travel

Hotels

Aviation

Logistics

Maritime

Hemas Holdings PLC: Market leading positions in Consumer and Healthcare


Presence across the Entire Leisure & Travel Value Chain

Market leadingH&PC Brands

Partnered with Global Maritime and Logistics Brands

Island-wide Coverage of Diagnostics & Healthcare Services

Sri Lanka’s Largest Pharma Supplier

52%

35%

5%

5% 3%

Healthcare

Consumer

Mobility

Leisure, Travel, & Aviation

Other

Group Revenue by SegmentQ1 FY 2019-20

Hemas Holdings PLC: Our Group

u Market cap: LKR 36.9 billion (US$ 210 million)

u Shareholding structure: Esufally family holds 64.3%, 35.7% public holding.

u Governance:

• HHL is governed by a 11-member board including 5 Independent Directors who are thought leaders in their respective fields of FMCG, Healthcare and Private Equity.

• The board is supported by a system of Business boards and Audit and Risk committees to uphold robust levels of governance.

u Management:

• Experienced senior management team with diverse backgrounds in FMCG, Healthcare, Finance, M&A, Supply Chain and Innovation.

• Top 60 business leaders are entitled to stock options.

u Debt-Equity ratio: 39.6%

u TSR over 5 years: 116.2%


HHL Group Performance: Five year summary


32 38 4350

64

19.2%16.9%

14.3%14.9%

28.5%

0%

10%

20%

30%

40%

15

25

35

45

55

65

75

FY 15 FY 16 FY 17 FY 18 FY 19

LKR

Billi

ons

Group Revenue and % Growth

FY 2014 – FY 2019

3.44.0

4.84.2

5.7

10.4% 10.4%11.0%

8.5%8.8%

0%

2%

4%

6%

8%

10%

12%

FY 15 FY 16 FY 17 FY 18 FY 190

2

4

6

LKR

Billi

ons

EBIT and EBIT margin (%)

FY 2014 – FY 2019

Hemas Journey: 70 years of serving the nation


1948

Started distributing “Seven Seas” OTC products

Acquired leading pharmaceutical manufacturing firm

2013

Widened array of Home & Personal care (H&PC) brands

1980s

Extended into the hospital space

2007

Extended in to travel and tourism

1970s

IPO on the Colombo Stock Exchange

2003

Ventured into manufacturing personal care products

1960s

2018

Acquired Sri Lanka’s largest stationery brand

Sold Power Business

2014

We do this by building strong consumer brands and providing access to a wide range of affordable healthcare solutions…


• Exceptional supply chain solutions for innovator medicines in emerging markets

• Superior range of OTC and Wellness offerings, including own brands

• Excellence in pharma manufacturing and self sufficiency in core therapies

Delivering quality medicines and therapies to patients who need them

• Wide portfolio of tertiary healthcare services in our hospitals

• Focus on wellness, screening and early detection through our lab network

Providing Affordable healthcare and diagnostics services

• Consolidate market-leading positions in H&PC, and School & Office

• Expand share-of-wallet in branded Consumer products

• Deepen equity positions through premiumisation and localisation

Developing a portfolio of consumer brands that delight

• Grow Kumarika brand platform in select South Asian markets

• Selective expansion of consumer portfolio into emerging South Asia

Tapping into the emerging Asian consumer

… And connecting suppliers with their customers, travellers with unique experiences and digital-first driven Wellness solutions


• A digital-first access point for a range of Wellness products and services

• Connect the medical community with their patients and high quality therapies

Connect patients to excellent digital health solutions

• Drive superior mobility solutions to serve the region’s logistics needs

• Extend into 3PL and last-mile RTM solutions

Serving the region’s logistics and route-to-market needs

• Focus on building out a portfolio of experiential assets

• Serve the aviation and cargo needs of the region

Experiential leisure to upscale travellers

u Sri Lanka’s household consumption grows at 4%, and personal care (H&PC) categories are highly penetrated.

u A weaker economic environment has kept consumer demand anemic over two years.

u Volume growth is led by emerging categories such as feminine hygiene as well as hair and skin, and price growth is driven by premiumization.

u Modern trade represents between 15%–17% of retail sales, expansion of the channel underpins growth in consumption.

u Hemas H&PC consistently outperformed the market by delighting customers with a continuous refreshment of our portfolio.

u We maintain depth of distribution of our market-leading brands in sizeable categories.


Household Final Consumption in Constant LKR Mn2014–2018

Source: Department of Census & Statistics

Sri Lanka FMCG Sector Value Growth & Hemas HPC growth2015–2018

Source: Nielsen Sri Lanka

Industry Focus: Home & Personal Care Sri Lanka—driving branded personal care consumption in emerging categories

0

2,000

4,000

6,000

8,000

2014 2015 2016 2017 2018

CAGR: 3.9%

5.80% 7.80%

-0.10% -0.10%

15.10%

8.60% 7.00% 6.40%

2015 2016 2017 2018-5%0%5%

10%15%20%

FMCG Hemas HPC

u Rapid growth of personal care consumption in emerging middle class, adding nearly 30Mn consumers through 2030.

u Seeking functional, modern formats of recognizable herbal personal care traditions.

u Rapid premiumization in consumption of FMCG

u Relative under-penetration of key categories such as shampoo, feminine hygiene and oral care present opportunities.

u Hemas selectively positions in under-penetrated categories, leading with the herbal equity of Kumarika.

u Targeting a combined population of 250Mn with current product offerings in Bangladesh and India.


11.5%13.5%

9.1%10.3%

FY 14 FY 15 FY 16 FY 170%

5%

10%

15%

FMCG Sales Growth, Bangladesh FY 14 – FY 17

Home & Personal Care—International: Taking the herbal beauty equity of Kumarika to select South Asian markets

Source: FMCG Industry Review of Bangladesh, EBL Securities Bangladesh, 21st June 2018

Bangladesh & West Bengal population =

250Mn

u Education: an investible asset for the Sri Lankan family:

• 4.5 million school going population, with rapid rise of per-child education spend.

• Sri Lankan families place high importance on education, and are seeking higher functionality, reliable brands and competitive edge for children.

u Acquisition of 75.1% of Atlas Axillia—Sri Lanka’s leading School consumer brand:

• Hemas acquired Atlas for a consideration of LKR 5.7Bn (10x PE), the business will add 15% to revenues.

• The brand holds a market leading position with over 40% share, and has been voted the “Sri Lanka’s Most Loved Brand of 2017

• Atlas introduced seasonality to our business due to the importance of the Q3 back to school season.

• Atlas consolidates Hemas market leading position in Sri Lankan consumer brands.


1,018

1,448

2,066

2010 2013 20160

500

1,000

1,500

2,000

2,500

Monthly Household Education Spend2010–2016

School & Office Supplies: Strong outlook as education spending deepens in importance to the South Asian householder

Source: Sri Lanka Household Consumption Survey, 2016; DCS.

CAGR: 12.5%

Healthcare: Rethinking private healthcare and widening access to medicines, wellness products and healthcare services

u Healthcare spend driven by growing burden of NCDs.

u Middle class consumers seeking convenience: 50% of patients use private outpatient services.

u State encouraging more domestic manufacturing of pharmaceuticals in the current 85%+ import market.

u Tele-medicine, direct-to-consumer pharma delivery gaining traction as more patients seek to bypass channeling services and seek healthcare on demand.

u Hemas’ extending leading position in pharmaceutical import and distribution to expanding manufacturing

u Extending mid-tier hospital and laboratory business into more complex tertiary procedures and diagnostics.


3.0%2.6% 2.8% 2.8% 3.0%

2013 2014 2015 2016 20170%

2%

4%

CHE % GDP

Current spending on health as a % of GDP2013 – 2017

Source: CBSL, National Health Accounts of Sri Lanka, Sri Lanka Healthcare Financing Profile, WHO, 2017

u Colombo Port throughput grew by 5% for the 1H 2019.

u Colombo Port ranked as the fastest growing port globally by Alphaliner in 1H 18/19

u Domestic logistics industry estimated to be USD 100Bn growing annual at 10-12%.

u More customers demand end to end supply chain solutions from logistics operators.

u Infrastructure development via ports, airports and expressways, FTZs adding to total logistics capacity.

u Port of Colombo saw a YoY growth 13.5% in 2018, transshipment volume growth at Colombo port was 20%.

u Hemas Mobility solutions encompass the spectrum of transportation, and is seeking to capitalize on both first, middle and last-mile delivery solutions.


Mobility: Capitalising on Sri Lanka’s excellent geo-strategic location

5.0 6.0 6.0

7.2

3.6

2015 2016 2017 2018 2019 1H0Mn

2Mn

4Mn

6Mn

8Mn

Colombo Port’s Throughput (TEU) 2015 – 2017

Source: Sri Lanka Ports Authority

Leisure: Focusing on experiential leisure with an asset-light investment strategy

u Sri Lanka is ranked the No.1 travel destination in 2019 by Lonely Planet and continues to be a rich, yet-to-be discovered destination for many travellers.

u Long haul travellers (Europe, Australia) continue to contribute significantly to source markets.

u Rise of Asian travellers exploring the island and changing tourism

u “So Sri Lanka” amplifier campaign aimed at engages typical millennial travel exploration debuted at the World Travel Mart in London.

u Hemas LTA segment is focussed on experiential leisure and Sri Lanka’s geo-location advantages for major aviation and air-cargo networks.

u Represents Emirates, Malaysian Airlines, Indigo and China Southern’s aviation interests in the country.


1.8Mn2.1Mn 2.1Mn

2.3Mn

1.0Mn

75% 75% 73% 75%

0.0

0.2

0.4

0.6

0.8

2015 2016 2017 2018 2019 1H0Mn

1Mn

2Mn

3Mn

4Mn

Tourist Arrivals and Occupancy2015 – 2018

Tourist Arrivals Occupancy

Source: Sri Lanka Tourism Development Authority

u The Easter Sunday Terror Attacks of 21st April, 2019 had a major impact on arrivals and bookings in the leisure segment, but a slow revival is being experienced.


Overview: Q1 FY 2019–2020• Strategic Priorities Update• Group Operational Highlights• Sector Performance

Group Update: Despite the preliminary setback of FY 20 we have been executing on our Strategic priorities and capacity building investments

u Profit improvement, resilience building and operating model improvement projects to build an execution-focussed organization

u Shape the portfolio around regional Consumer and Healthcare leadership

u Disposed N*able in early Q2

u Ramping up our international market presence by investing behind the growth of Bangladesh, West Bengal and Myanmar.

u Ensuring our Morison Pharmaceutical Plant is physically completed and operational in late 2020.

u Profit improvement projects to deliver results during the financial year

u Building resilience in our route-to-market capability in Consumer and Pharmaceuticals

u Ramping up the operations of our new logistics park.


Strong emphasis on building an organization focused on execution

The aftermath of the Easter Sunday Terror attacks impacted the normal course of business at the start of our fiscal year, but we are working hard to return to normal levels of business. Our focus and priorities this year remain

Q1 FY 2019–20 Operations Summary: Consumer businesses experienced a slowdown

u Challenging quarter with revenues below 2.3% last year, primarily as a result of the terrorist attacks of 21st April with the aftermath causing economic slowdown and challenging trading conditions.

u In Q1, both H&PC SL and Atlas have been impacted by poor consumer sentiment coupled with weak purchasing power and anti-communal pressures. This resulted in a considerable decline in performance.

u Profitability impact was higher as the Group recorded a breakeven in operating profits of Rs.19Mn

u Key factors in this have been in the business mix with higher margin Consumer businesses experiencing a slowdown while lower margin healthcare businesses grew revenue by 7.6%.

u In line with the sharp downturn in the tourism industry, Leisure and Travel interests have been directly impacted and incurred an operating loss of Rs.179Mn during the quarter.

u Similarly, Morison and N*able too dragged down group performance.

u During the quarter, the Group was also impacted by a number of one offs of Rs.130Mn including a charge from the adoption of SLFRS 16.

u Excluding one-offs operating profit for the period stood at Rs.150Mn over Rs.895Mn LY


Challenging quarter as higher margin consumer segment sales declined. Modest

recovery is experienced during early Q2.

3,9395,366 4,599

5,116

6,381

6,864682

792 687

623

718 614

770

247 435

7.8%

6.6%

0.1%0%

2%

4%

6%

8%

10%

12%

FY 18 - Q1 FY 19 - Q1 FY 20 - Q10Mn

2,000Mn

4,000Mn

6,000Mn

8,000Mn

10,000Mn

12,000Mn

14,000Mn

16,000Mn

Sector Revenue & EBIT Margin (%)Q1 FY 18 – Q1 FY 20

ConsumerHealthcare

LTAMobility

OtherEBIT margin

Q1FY 2019–20 Sector Highlights


Consumer

Healthcare

u Weaker performance from H&PC SL and Atlasu Disruption to the sales and distribution led to a fall in the General Trade

performanceu Schools were also closed for nearly half the quarter

u H&PC Bangladesh relaunched Kumarika in mid May. Volumes grew in Soap and facewash category over last year but steady pick up in West Bengal

u Subdued performance in the Mori OTC segment

Mobility

Leisure

Rev (LKR Mn)

%Growth

EBIT (LKR Mn)

%Growth

4,599 -14.3% 16 -97.2%

Rev (LKR Mn)

%Growth

EBIT (LKR Mn)

%Growth

6,864 7.6% 380 -23.9%

Rev (LKR Mn)

%Growth

EBIT (LKR Mn)

%Growth

614 -14.6% 121 -44.5%

Rev (LKR Mn)

%Growth

EBIT (LKR Mn)

%Growth

687 -13.3% (179) -27.4%

u Pharmaceutical distribution performance satisfactory as sales improved and pricing pressure was relieved through the Fx correction on price-controlled medicines in May

u Hemas Hospitals achieved an overall average occupancy of 50%u Production interruptions at the Morison plant post Easter attacks. u Excluding the SLFRS 16 and SLFRS 9 impact mainly on hospitals and pharma distribution,

and increased debtor provisioning, underlying operating profit decline stood at 12%

u Delays in the new Spectra distribution center ramp-up plans dragged down the sector performance

u Additionally, segment profitability is impacted by the increased depreciation and finance costs resulting from the new facility

u Loss of tourist arrivals from the key markets dragged the sector revenue and profitability down significantly.

u A series of stringent cost control initiatives offset the unfavorable impact to profitability from a significant revenue loss.

u Cancellations of tour groups in inbound and outbound segment further led to a decline in profitability.


Most Recent Quarter Performance: Q1, FY 2019–2020• Group Operational Highlights• Quarterly Sector Update

— Consumer – Domestic— Consumer – International— Healthcare— Mobility— Leisure, Travel and Aviation

Q1 (3 months) FY 2019–20: Group Operational Highlights


Weaker topline driven by Consumer and Leisure segment, but Healthcare performance was robust; one-offs and working capital costs resulted in further earnings pressure

Revenue EBIT Earnings

• Group experienced weaker consumer sentiment dampening performance over LY.

• 2.3% dip in revenue over last year, primarily due to H&PC SL, Atlas, Hospitals, LTA and Mobility recording poor performance.

• International revenues grew 7.4% supported by good traction in West Bengal.

• Business mix: Sales declines flowed through to EBIT, compressing margins across major profit contributors.

• OP margin stood at 0.1% (6.6% LY) as a result.

• Additionally, a number of one offs totallingup to Rs.130Mn including a charge from the adoption of SLFRS 16 were incurred.

• Increased Logistics and Pharma financing and working capital costs:⎼ Working capital funding for Pharma due

to delays in government receivables

• Further, a timing difference in the dividend tax charge of Rs.278Mn following the declaration of dividend at the recent AGM combined with the Debenture settlement

13,505 13,198

FY 19 - Q1 FY 20 - Q10Mn

4,000Mn

8,000Mn

12,000Mn

16,000Mn-2.3%21.3%

554

-426

FY 19 - Q1 FY 20 - Q1-500Mn

-300Mn

-100Mn

100Mn

300Mn

500Mn

-176.8%896

20

FY 19 - Q1 FY 20 - Q10Mn

200Mn

400Mn

600Mn

800Mn

1,000Mn

-97.8%

3.5% -20.2%

Consumer Sector Performance: Q1 FY 2019–2020


Business Update

u Depressed demand in the first half of Q1 over security concerns and school closures affecting retailer and consumer purchasing.

u Hemas Consumer categories experienced sales decline as a result of anti-communal sentiment arising in the aftermath of the Easter attacks, in addition to overall categories declining by 4%.

Sector Revenues & EBIT in LKRQ1 FY 18 – Q1 FY 20

3,9395,366 4,599

526 569

16 0Mn

200Mn

400Mn

600Mn

FY 18 - Q1 FY 19 - Q1 FY 20 - Q10Mn

1,000Mn

2,000Mn

3,000Mn

4,000Mn

5,000Mn

6,000Mn

Sector Revenue EBIT

No. 1 Baby Care Brand

No. 2 Washing Powder Brand

No. 1 School & Office Supplies Brand

No. 2 Oral Care Player

No. 2 Feminine Hygiene Brand

No. 1 Hair Oil

No. 1 Beauty SoapSource: Restated revenue in accordance with IFRS 15

International entry to Bangladesh with our brand Kumarika


International Segment as a % of total H&PC segmentQ1 FY 18 – Q1 FY 20 u New brand architecture on Kumarika was introduced to the market in

May 2019

u Continued focus on expanding into rural markets in Bangladesh

u Introduced a marbleized herbal beauty soap under Kumarika brand in Bangladesh and continue to push visibility of Kumarika facewash

u Continuing to drive early stage performance of West Bengal

Sector Highlights

Herbal Beauty Soap Feminine Hygiene

Face WashHair Oil

85% 83% 78%

15% 17% 22%

FY 18 - Q1 FY 19 - Q1 FY 20 - Q10%

20%

40%

60%

80%

100%

H&PC Sri Lanka H&PC International

Business Update

u H&PC International grew by 7% in Q1, with revived sales post Kumarika relaunch in May.

u Kumarika maintained its VAHO market share through the year at 19%

u Total retail availability now over 200K, as restructured distribution benefits kick in.

New Image Pending

Healthcare Sector Performance: Q1 FY 2019–2020


Hemas Healthcare Sectors

Business Update

u Modest improvement in topline. Steady growth in pharma distribution business followed by the price increase on regulated drugs.

u Excluding the SLFRS 16 impact mainly on Hospitals and SLFRS 9 impact resulting from increased debtor provisioning, the underlying operating profit decline stood at 12%

u Launched the Hemas Health mobile app


5,1166,381

6,864

509 499

380

0Mn

200Mn

400Mn

600Mn

FY 18 - Q1 FY 19 - Q1 FY 20 - Q10Mn

2,000Mn

4,000Mn

6,000Mn

8,000Mn

Sector Revenue EBIT

Source: Restated revenue in accordance with IFRS 15

Pharma Manufacturing

Pharma Distribution

Digital Healthcare

Hospitals

1

2

3

4

u Hemas Hospitals clinched three coveted awards for Patient Care Initiative of the Year, Service Delivery Innovation Initiative of the Year, and Health Promotion Initiative of the Year at the Healthcare Asia Awards 2019

u Ayubo.life accredited by Health Informatics Society of Sri Lanka (HISSL) for digital and data security.

Mobility Sector Performance: Q1 FY 2019–2020


Business Update

u Delays in filling up the warehousing capacity

u Increased depreciation and finance costs from the new facility


623 718 614

188 217

121

0Mn

100Mn

200Mn

300Mn

400Mn

FY 18 - Q1 FY 19 - Q1 FY 20 - Q10Mn

200Mn

400Mn

600Mn

800Mn

1,000Mn

Sector Revenue EBIT

Logistics

Maritime

Leisure, Travel & Aviation Sector Performance: Q1 FY 2019–2020


Business Update

u 42% average occupancy across owned hotels, 20% lower than LY; Rates at all properties were reduced in order to uplift occupancy. RevPAR of Rs. 8,059 for the quarter is a 27% decrease over LY.

u A one-year moratorium on loans was granted along with a VAT revision to 7%.

u Travel and Aviation recorded a decline in performance due to inbound travel seeing a steep decine coupled with lower demand for corporate travel.

u In addition, Serendib Leisure Management Limited took over the management of Tri Lanka Koggala in May 2019, as well as the provision of marketing services for Stafford Bungalow Nuwara Eliya.


682 792

687

-200.0

-140.0-179.0

-300Mn

-200Mn

-100Mn

0Mn

100Mn

FY 18 - Q1 FY 19 - Q1 FY 20 - Q10Mn

200Mn

400Mn

600Mn

800Mn

1,000Mn

Sector Revenue EBIT

Hotels

HEMAS TRAVELS

Travel

Aviation


Investment HighlightsDigital & Innovation People & TalentSustainability & Wellness

Investment Highlights


39.0%

15.5%

-39.1%FY 17 FY 18 FY 19

-50%

-25%

0%

25%

50%

Total Shareholder Return (%) Return on Equity (%)

EPS Walk

13.0%10.5%

1.0%

FY 18 - Q1 FY 19 - Q1 FY 20 - Q10%

10%

20%

Return on Capital Employed

Increase

Decrease

Total

0.93

-0.71-158%

-10%-27%

19%

EPS FY 19 - Q1 OperatingProfit

Finance Cost Income Tax NCI EPS FY 20 - Q1-2

-1

0

1

2

11.2%8.6%

-6.2%

FY 18 - Q1 FY 19 - Q1 FY 20 - Q1-10%

0%

10%

20%

Driving digital and innovation


u Being driven by Innovation is a core value of Hemas Group, and our digital strategy is at the forefront of our drive towards reinvention in preparation for the business world of tomorrow.

“Adahas”

Ayubo.lifeFocusing on making Health and wellness more accessible digitally, connecting wellness experts within a click of button and maximizing impact with wellness analytics.

The Hemas Slingshot Program aims to provide talented entrepreneurs/ inventors a chance to commercialize inventions/ projects which fall into the strategic areas of our operations.

The “Adahas” Program of Hemas is an internal crowdsourcing effort aimed identifying and implementing good business related ideas among our 7,000+ team. The best ideas are evaluated and already being implemented.

We continue to invest in people


Be your best self

• “360 You”, the Hemas Employee Value Proposition was launched in October 2017 and is an expression of how Hemas commits to enrich employee lives through the acknowledgement that an employee brings their whole self to work

• As an equal opportunity employer, Hemas was highlighted as a case study by #SheWorks Sri Lanka, an IFC led programme in our efforts to provide employer-supported child support.

• Hemas has also introduced flexible working as a policy, and is among the few organisations to offer paternity and adoption leave in addition to maternity leave.

• Successful completion of a third year development program in partnership with Indian Institute of Management Bangalore (IIMB), to prepare Hemas Future Leaders.

• Over 90% of those that went through this programme have progressed in their careers through enriched job scopes and promotions.

Future Leaders’

Programme

Sustainability & Wellness


Reduction of consumption of water by 50%

50% of reduction of energy consumption by 2022 and by 2025 to be offset by renewable energy

Group Environmental Goals by 2025 Engaging with Our Community

Employee WellnessHemas is on the mission to become the healthiest workforce in Sri Lanka. Our goals for 20/20.

• 56 Pre schools• 3500+ children impacted• 150 Piyawara teachers

AYATI is a long-term initiative with three main aims:• Sri Lanka Army Completes the Construction of the AYATI Center• Changing the mindset of the public to eliminate any stigma and promote

acceptance of children with disabilities• Extending the services to the rural areas of Sri Lanka in time to come

• Scholarship programme in partnership with ministry of child affairs

• 219 Children between 5-10 years offered a sum of Rs 2000/= month

Blood Pressure

25%Cholesterol

25%Halt the

Rise of Obesity

Raised Blood Sugar Levels

Physical Inactivity

50%

% Salt Used in Canteens

5%

Tobacco Usage

5%

Worksite Health Score

50%

Reforesting Zero waste to landfills


DisclaimerThe material in this presentation has been prepared by Hemas Holdings PLC (“Hemas”) and is general background information about Hemas’ activities current as at the date of this presentation. This information is given in summary form and does not purport to be complete. Information in this presentation, including forecast financial information, should not be considered as advice or a recommendation to investors or potential investors in relation to holding, purchasing or selling securities or other financial products or instruments and does not take into account your particular investment objectives, financial situation or needs. Before acting on any information you should consider the appropriateness of the information having regard to these matters, any relevant offer document and in particular, you should seek independent financial advice. All securities and financial product or instrument transactions involve risks, which include (among others) the risk of adverse or unanticipated market, financial or political developments and, in international transactions, currency risk.

This presentation may contain forward looking statements including statements regarding our intent, belief or current expectations with respect to Hemas’ businesses and operations, market conditions, results of operation and financial condition, capital adequacy, specific provisions and risk management practices. Hemas does not undertake any obligation to publicly release the result of any revisions to these forward looking statements to reflect events or circumstances after the date hereof to reflect the occurrence of unanticipated events. While due care has been used in the preparation of forecast information, actual results may vary in a materially positive or negative manner. Forecasts and hypothetical examples are subject to uncertainty and contingencies outside Hemas’ control. Past performance is not a reliable indication of future performance. Unless otherwise specified all information is for the quarter ended 30th June, 2019.

CONFIDENTIALITY AGREEMENT:Any confidential information discussed in this presentation shall be used by the receiving party exclusively for the purposes of

fulfilling the receiving party’s obligation and for no other purpose except with the consent of the disclosing party.

Contact Investor RelationsTelephone: +94 11 4 731 731 (Ext. 1278)

Email: [email protected]: http://www.hemas.com

Hemas Holdings PLC Hemas House, 75, Braybrooke Place,

Colombo 2, Sri Lanka

hemas investor presentation q1 20202010 2013 2016 0 500 1,000 1,500 2,000 2,500 monthly household...

Documents